BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33338041)

  • 1. Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial.
    Medkour H; Bitam I; Laidoudi Y; Lafri I; Lounas A; Hamidat HK; Mekroud A; Varloud M; Davoust B; Mediannikov O
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008947. PubMed ID: 33338041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, blinded, controlled clinical trial comparing the efficacy of aminosidine (paromomycin)-allopurinol combination with the efficacy of meglumine antimoniate-allopurinol combination for the treatment of canine leishmaniosis due to Leishmania infantum.
    Kasabalis D; Chatzis MK; Apostolidis K; Petanides T; Athanasiou LV; Xenoulis PG; Mataragka A; Ikonomopoulos J; Leontides LS; Saridomichelakis MN
    Exp Parasitol; 2020 Jul; 214():107903. PubMed ID: 32360142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis.
    Segarra S; Miró G; Montoya A; Pardo-Marín L; Boqué N; Ferrer L; Cerón J
    Vet Parasitol; 2017 May; 239():50-56. PubMed ID: 28495197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
    Dos Santos CCP; Ramos GS; De Paula RC; Faria KF; Moreira POL; Pereira RA; Melo MN; Tafuri WL; Demicheli C; Ribeiro RR; Azevedo EG; Do Monte-Neto R; Da Silva SM; Frézard F
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early reduction of Leishmania infantum-specific antibodies and blood parasitemia during treatment in dogs with moderate or severe disease.
    Solano-Gallego L; Di Filippo L; Ordeix L; Planellas M; Roura X; Altet L; Martínez-Orellana P; Montserrat S
    Parasit Vectors; 2016 May; 9(1):235. PubMed ID: 27160317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
    Gonçalves G; Campos MP; Gonçalves AS; Medeiros LCS; Figueiredo FB
    Parasit Vectors; 2021 Dec; 14(1):599. PubMed ID: 34886876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
    Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
    Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of nephrotoxicity and ototoxicity of aminosidine (paromomycin)-allopurinol combination in dogs with leishmaniosis due to Leishmania infantum: A randomized, blinded, controlled study.
    Kasabalis D; Chatzis MK; Apostolidis K; Xenoulis PG; Buono A; Petanides T; Leontides LS; Polizopoulou ZS; Steiner JM; Suchodolski JS; Saridomichelakis MN
    Exp Parasitol; 2019 Nov; 206():107768. PubMed ID: 31539540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short term impacts of meglumine antimoniate treatment on kidney function in dogs with clinical leishmaniosis.
    Daza González MA; Miró G; Fermín Rodríguez M; Rupérez Noguer C; Fragío Arnold C
    Res Vet Sci; 2019 Oct; 126():131-138. PubMed ID: 31491669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.
    Dos Santos Nogueira F; Avino VC; Galvis-Ovallos F; Pereira-Chioccola VL; Moreira MAB; Romariz APPL; Molla LM; Menz I
    Parasit Vectors; 2019 Feb; 12(1):79. PubMed ID: 30736866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
    Castro RS; de Amorim IFG; Pereira RA; Silva SM; Pinheiro LJ; Pinto AJW; Azevedo EG; Demicheli C; Caliari MMV; Mosser DM; Michalick MSM; Frezard FJG; Tafuri WL
    Vet Parasitol; 2018 Jan; 250():22-29. PubMed ID: 29329619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.
    Solano-Gallego L; Riera C; Roura X; Iniesta L; Gallego M; Valladares JE; Fisa R; Castillejo S; Alberola J; Ferrer L; Arboix M; Portús M
    Vet Parasitol; 2001 Apr; 96(4):265-76. PubMed ID: 11267753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR-2 and TLR-4 transcriptions in unstimulated blood from dogs with leishmaniosis due to Leishmania infantum at the time of diagnosis and during follow-up treatment.
    Montserrat-Sangrà S; Alborch L; Ordeix L; Solano-Gallego L
    Vet Parasitol; 2016 Sep; 228():172-179. PubMed ID: 27692322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
    Oliva G; Foglia Manzillo V; Pagano A
    Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania infantum-specific IFN-γ production in stimulated blood from dogs with clinical leishmaniosis at diagnosis and during treatment.
    Martínez-Orellana P; Marí-Martorell D; Montserrat-Sangrà S; Ordeix L; Baneth G; Solano-Gallego L
    Vet Parasitol; 2017 Dec; 248():39-47. PubMed ID: 29173539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
    Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
    Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and serological follow-up in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate.
    Pasa S; Toz SO; Voyvoda H; Ozbel Y
    Vet Parasitol; 2005 Mar; 128(3-4):243-9. PubMed ID: 15740861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
    Daza González MA; Fragío Arnold C; Fermín Rodríguez M; Checa R; Montoya A; Portero Fuentes M; Rupérez Noguer C; Martínez Subiela S; Cerón JJ; Miró G
    Vet J; 2019 Mar; 245():22-28. PubMed ID: 30819422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
    Manna L; Vitale F; Reale S; Picillo E; Neglia G; Vescio F; Gravino AE
    Vet J; 2009 Dec; 182(3):441-5. PubMed ID: 18818112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy.
    de Jong MK; Rappoldt A; Broere F; Piek CJ
    Parasit Vectors; 2023 May; 16(1):163. PubMed ID: 37189181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.